

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

AMENDMENTS TO THE CLAIMS

1. (Currently amended) A method for binding cells, comprising:  
providing said cells;  
contacting said cells with ~~an antibody that binds to a surface structure on said cells, wherein said surface structure is also capable of binding antibody 97A6, which is produced by the hybridoma on deposit as No. DSM ACC 2297, to produce a cell-antibody complex, and~~  
wherein said cells are selected from the group consisting of basophils, mast cells, precursor cells of basophils, and precursor cells of mast cells.
2. (Currently amended) The method of Claim 1, comprising the further steps of:  
separating the cell-antibody complex from unbound cells and/or unbound antibody, and  
detecting a level of the cell-antibody complex ~~said cells or surface structures.~~
3. (Canceled)
4. The method of Claim 1, comprising the further step of quantifying said cell-  
antibody complexes or surface structures.
5. (Canceled)
6. (Canceled)
7. (Canceled)
8. (Currently amended) ~~A~~ The method for the analysis of hematopoiesis, comprising a method as in of Claim 1, further comprising the step of analyzing hematopoiesis in terms of said cells.
9. (Original) The method of Claim 1, further comprising the step of determining the extent to which basophils are activated.
10. (Original) The method of Claim 2, wherein the antibody is joined to a marker.
11. (Original) The method of Claim 10, wherein the antibody is joined to a fluorescent marker.
12. (Currently amended) The method of Claim 2, wherein detection of ~~bound antibodies~~ cell-antibody complex is accomplished by way of ~~usual~~ immunological detection methods, such as ELISA or FACS analysis.

**Appl. No.** : **09/996,030**  
**Filed** : **November 16, 2001**

13. (Currently amended) The method of Claim 2, further comprising the step of detecting activated basophils.

14. (Original) The method of Claim 13, further comprising the step of determining the extent to which basophils are activated.

15. (Canceled)

16. (Withdrawn) A method for the diagnostic classification of a tumor, comprising providing a sample of said tumor, which comprises cells having a surface structure, and contacting said surface structure with an antibody capable of binding said surface structure, wherein said surface structure is also capable of binding to antibody 97A6, which is produced by the hybridoma on deposit as No. DSM ACC 2297.

17. (Withdrawn) The method of Claim 16, wherein the tumor is leukemia.

18. (Withdrawn) A method for investigating allergies, comprising pre-incubating a blood sample comprising cells with an agent that is suspected of triggering an allergic reaction; incubating said pre-incubated blood sample with an antibody capable of binding to a surface structure of said cells, wherein said surface structure is also capable of binding to antibody 97A6, which is produced by the hybridoma on deposit as No. DSM ACC 2297; and quantifying antibodies bound to cells in said blood sample.

19. (Withdrawn) A method of providing hematopoietic precursor cells that can differentiate into mast cells or basophils, comprising: providing bone marrow cells having a surface structure from an organism; incubating said bone marrow cells with an antibody capable of binding to said surface structure, wherein said surface structure is also capable of binding to antibody 97A6, which is produced by the hybridoma on deposit as No. DSM ACC 2297; and isolating antibody-bound cells from the incubated bone marrow cells.

20. (Withdrawn) A substantially pure population of cells, wherein said cells are capable of being bound by a reagent that binds specifically to a surface structure on said cells, wherein said surface structure is also capable of binding to antibody 97A6, which is produced by the hybridoma on deposit as No. DSM ACC 2297; and wherein said cells are selected from the group consisting of basophils, mast cells, precursor cells of basophils, and precursor cells of mast cells.

21. (Withdrawn) A reagent for binding cells, comprising an antibody capable of binding to a surface structure of said cells, wherein said surface structure is also capable of

**Appl. No.** : **09/996,030**  
**Filed** : **November 16, 2001**

binding to the antibody 97A6, and wherein said cells are selected from the group consisting of basophils, mast cells, precursor cells of basophils, and precursor cells of mast cells.

22. (New) The method of claim 1, wherein said cells are provided as being contained within a patient sample, wherein said patient sample is selected from the group consisting of tissue biopsies, bone marrow biopsies, and blood samples.